Provided by Tiger Fintech (Singapore) Pte. Ltd.

Genprex, Inc.

0.2848
+0.01836.87%
Post-market: 0.28600.0012+0.42%19:57 EDT
Volume:2.01M
Turnover:549.36K
Market Cap:6.88M
PE:-0.05
High:0.2900
Open:0.2700
Low:0.2500
Close:0.2665
Loading ...

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination With Tecentriq® in Extensive Stage Small Cell Lung Cancer

THOMSON REUTERS
·
16 Dec 2024

Genprex Signs License Deal for University of Michigan's Gene Therapy to Treat Lung Cancer

MT Newswires Live
·
20 Nov 2024

Genprex signs exclusive license agreement with University of Michigan

TIPRANKS
·
20 Nov 2024

Genprex Signs Exclusive License to Additional Gene Therapy Technologies With the University of Michigan for the Treatment of Lung Cancer

THOMSON REUTERS
·
20 Nov 2024

BRIEF-Genprex Inc Receives Nasdaq Notice For Non-Compliance With Equity Requirement

Reuters
·
20 Nov 2024

Genprex Inc - Receives Nasdaq Notice for Non-Compliance With Equity Requirement

THOMSON REUTERS
·
20 Nov 2024

Genprex Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
13 Nov 2024

Genprex Inc expected to post a loss of 68 cents a share - Earnings Preview

Reuters
·
13 Nov 2024

Genprex Inc expected to post a loss of $1.93 a share - Earnings Preview

Reuters
·
08 Nov 2024

BRIEF-Genprex Inc Regains Compliance With NASDAQ Minimum Bid Price Requirement

Reuters
·
06 Nov 2024

Genprex Reports Positive Preclinical Data on Reqorsa Gene Therapy; Regains Nasdaq Compliance

MT Newswires Live
·
06 Nov 2024

Genprex to present positive preclinical data from Reqorsa Gene Therapy study

TIPRANKS
·
05 Nov 2024

Genprex Inc: Regains Compliance With Nasdaq Minimum Bid Price Requirement

THOMSON REUTERS
·
05 Nov 2024